Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen

por Jager, N. G. L., Rosing, H., Linn, S. C., Schellens, J. H. M., Beijnen, J. H.
Publicado em 2012

Bioanalysis of the novel peptide anticancer drug kahalalide F in human plasma by h.p.l.c. under basic conditions coupled with positive turbo-ionspray tandem mass spectrometry

por Stokvis, E, Rosing, H, López-Lázaro, L, Jimeno, J M, Supko, J G, Schellens, J H M, Beijnen, J H
Publicado em 2002

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation

por Hendrikx, J J M A, Lagas, J S, Wagenaar, E, Rosing, H, Schellens, J H M, Beijnen, J H, Schinkel, A H
Publicado em 2014

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.

por Schellens, J. H., Creemers, G. J., Beijnen, J. H., Rosing, H., de Boer-Dennert, M., McDonald, M., Davies, B., Verweij, J.
Publicado em 1996

Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid.

por Burger, D M, Rosing, H, ten Napel, C H, Duyts, T, Meenhorst, P L, Mulder, J W, Koks, C H, Bult, A, Beijnen, J H
Publicado em 1994

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients

por van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V., Sanghvi, M., Tibben, M. M., Gebretensae, A., Schellens, J. H. M., Beijnen, J. H.
Publicado no Cancer Chemother Pharmacol (2017)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients

por van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V., Sanghvi, M., Tibben, M. M., Gebretensae, A., Schellens, J. H. M., Beijnen, J. H.
Publicado no Cancer Chemother Pharmacol (2017)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

por Malingré, M M, Beijnen, J H, Rosing, H, Koopman, F J, Jewell, R C, Paul, E M, Huinink, W W Ten Bokkel, Schellens, J H M
Publicado em 2001

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry

por Kip, A.E., Rosing, H., Hillebrand, M.J.X., Castro, M.M., Gomez, M.A., Schellens, J.H.M., Beijnen, J.H., Dorlo, T.P.C.
Publicado no J Chromatogr B Analyt Technol Biomed Life Sci (2015)

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection

por Kip, A. E., Rosing, H., Hillebrand, M. J. X., Blesson, S., Mengesha, B., Diro, E., Hailu, A., Schellens, J. H. M., Beijnen, J. H., Dorlo, T. P. C.
Publicado no Antimicrob Agents Chemother (2016)

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic–pharmacodynamic study

por Joerger, M, Huitema, A D R, Huizing, M T, Willemse, P H B, de Graeff, A, Rosing, H, Schellens, J H M, Beijnen, J H, Vermorken, J B
Publicado em 2007

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen

por van Nuland, M., Vreman, R. A., ten Ham, R. M. T., de Vries Schultink, A. H. M., Rosing, H., Schellens, J. H. M., Beijnen, J. H., Hövels, A. M.
Publicado no Breast Cancer Res Treat (2018)

Oral topotecan: bioavailability and effect of food co-administration

por Herben, V M M, Rosing, H, Huinink, W W ten Bokkel, Zomeren, D M van, Batchelor, D, Doyle, E, Beusenberg, F D, Beijnen, J H, Schellens, J H M
Publicado em 1999

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients

por Malingré, M M, Schellens, J H M, Tellingen, O Van, Ouwehand, M, Bardelmeijer, H A, Rosing, H, Koopman, F J, Schot, M E, Huinink, W W Ten Bokkel, Beijnen, J H
Publicado em 2001

Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

por van Andel, Lotte, Zhang, Z., Lu, S., Kansra, V., Agarwal, S., Hughes, L., Tibben, M. M., Gebretensae, A., Lucas, L., Hillebrand, M. J. X., Rosing, H., Schellens, J. H. M., Beijnen, J. H.
Publicado no Invest New Drugs (2017)

A phase I and pharmacokinetic study of intraperitoneal topotecan

por Hofstra, L S, Bos, A M E, Vries, E G E de, Zee, A G J van der, Beijnen, J H, Rosing, H, Mulder, N H, Aalders, J G, Willemse, P H B
Publicado em 2001

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

por Bruin, M. A. C., Korse, C. M., van Wijnen, B., de Jong, V. M. T., Linn, S. C., van Triest, B., Rosing, H., Beijnen, J. H., van den Broek, D., Huitema, A. D. R.
Publicado no Eur J Clin Pharmacol (2020)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks

por Kerbusch, T, Groenewegen, G, Mathôt, R A A, Herben, V M M, ten Bokkel Huinink, W W, Swart, M, Ambaum, B, Rosing, H, Jansen, S, Voest, E E, Beijnen, J H, Schellens, J H M
Publicado em 2004

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

por Schoemaker, N E, van Kesteren, C, Rosing, H, Jansen, S, Swart, M, Lieverst, J, Fraier, D, Breda, M, Pellizzoni, C, Spinelli, R, Porro, M Grazia, Beijnen, J H, Schellens, J H M, ten Bokkel Huinink, WW
Publicado em 2002

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

por van der Noll, R., Smit, W. M., Wymenga, A. N. M., Boss, D. S., Grob, M., Huitema, A. D. R., Rosing, H., Tibben, M. M., Keessen, M., Rehorst, H., Beijnen, J. H., Schellens, J. H. M.
Publicado no Invest New Drugs (2015)